About Skybiotech Healthcare Limited
Data last updated:
Skybiotech Healthcare Limited is a public limited company based in Mumbai, Maharashtra, India. It operates in the business and IT consulting segment of the business process outsourcing sector. It was incorporated on 17 October 1983 and has been in existence for over 43 years.
The company is registered with the Registrar of Companies (ROC), Mumbai, under CIN L21001MH1983PLC031114. The company has 1 GST registration on record, which is no longer active. It is a listed company as per MCA records. Its shares are listed on BSE: 512036.
The company has an authorised share capital of ₹5 Cr and a paid-up capital of ₹1.92 Cr. It was formerly known as Kapil Cotex Ltd. It is led by directors including Poonam Prakash Rathi (Managing Director) and Rakesh Ramswaroop Somani.
Its last annual general meeting (AGM) was held on 25 September 2025, and its latest financial statements are for the year ended 31 March 2026. The registered office is at Mumbai, Maharashtra.
As per the latest consolidated financials for FY 2025-26, the company reported a revenue of ₹7.1 Cr, a growth of 0.7% compared to the previous year. For the same year it recorded a net loss of ₹1.11 Cr (net margin -15.6%) and EBITDA of -₹1.47 Cr (EBITDA margin -20.7%).
The company has 36 deals on record (36 market trades); the latest was in March 2025.
The current compliance status is marked as compliant by the Registrar of Companies. For more details, the company can be reached via its website satellitecorporate.com.
Company details
CIN history
Skybiotech Healthcare has 2 previous CINs, indicating changes in the company's corporate structure or registration details. The current CIN is L21001MH1983PLC031114, which is the unique identifier assigned by the Registrar of Companies.
| CIN | Status |
|---|---|
| L21001MH1983PLC031114 | Current |
| L17100MH1983PLC031114 | Previous |
| U17100MH1983PLC031114 | Previous |
Contact details
Skybiotech Healthcare Limited's registered office is in Mumbai, Maharashtra.
- Registered AddressShop No. 276 Dreams Mall L. B. S. Marg Near Bhandup Railway Station Bhandup (W, Est), Mumbai, Maharashtra, India – 400078
- IndustryBusiness Outsourcing, Business & IT Consulting
- Company details, directors and signatories
- Historical financials and ratios
- Shareholding pattern and group structure
- Charges with holder and property details
- Legal cases, compliance and MCA filings
Business activity
The main business activity of Skybiotech Healthcare is manufacturing. In detail, this covers textile, leather and other apparel products.
| Main activity group code | Main activity | Business activity code | Business activity | Share of turnover |
|---|---|---|---|---|
| C | Manufacturing | C2 | Textile, leather and other apparel products |
To see the full business activity and turnover split of Skybiotech Healthcare Limited, buy the company report.
Financials of Skybiotech Healthcare Limited
FY 2025-26 filings availableSkybiotech Healthcare Limited reported revenue of ₹7.1 Cr (up 0.7% YoY) for FY 2025-26.
Financial Highlights
FY 2025-26 · ConsolidatedRevenue vs Net Profit ₹ Cr
Margin trends
Financial summary ₹ Cr
| Metrics | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Income statement | ||
| Revenue | 7.10 | 7.05 |
| Revenue growth | +0.7% | - |
| EBITDA | (1.47) | (2.26) |
| EBITDA margin | -20.7% | -32.1% |
| Profit before tax | (1.66) | (2.43) |
| Net profit | (1.11) | (2.38) |
| Net profit margin | -15.6% | -33.8% |
| EPS (₹) | (6.70) | (12.37) |
| Balance sheet | ||
| Total assets | - | 17.74 |
| Net worth | - | 8.99 |
| Total debt | - | 7.20 |
| Cash & bank | - | (0.27) |
| Net working capital | - | (0.45) |
| Cash flow | ||
| Cash from operations | - | (1.04) |
| Cash from investing | - | (9.63) |
| Cash from financing | - | 1.24 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.49 | 1.83 | 0.96 | 1.92 | 2.39 | 1.02 | 2.52 | 1.60 |
| Revenue growth (YoY) | -79.5% | +79.4% | -61.9% | +20.0% | - | - | - | - |
| Other income | 0.06 | 0.15 | 0.08 | 0.04 | 0.03 | (0.18) | 0.15 | 0.04 |
| EBITDA | (0.53) | (0.88) | (0.44) | (0.22) | 0.08 | (1.08) | (0.31) | 0.03 |
| EBITDA margin | -108.2% | -48.1% | -45.8% | -11.5% | +3.3% | -105.9% | -12.3% | +1.9% |
| Depreciation | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | 0.15 | 0.14 | 0.13 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | (0.23) | 0.11 | 0.13 |
| Profit before tax | (0.58) | (0.85) | (0.48) | (0.30) | (0.02) | (1.18) | (0.41) | (0.19) |
| Tax | 0.00 | (0.55) | 0.00 | 0.00 | 0.00 | (0.10) | (0.02) | 0.06 |
| Net profit | (0.58) | (0.30) | (0.48) | (0.30) | (0.02) | (1.08) | (0.39) | (0.25) |
| EPS (₹) | (2.56) | (2.96) | (1.29) | (1.29) | 0.25 | (13.68) | (3.06) | 5.46 |
| Metrics | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Income statement | |||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | (0.13) | (0.10) | (0.12) | (0.06) | (0.05) | (0.07) | (0.10) |
| Profit before tax | (0.06) | 0.08 | 1.88 | (0.01) | (0.03) | (0.05) | (0.03) |
| Net profit | (0.06) | (0.05) | 0.01 | (0.03) | (0.02) | (0.05) | (0.06) |
| EPS (₹) | (1.18) | 0.31 | 8.02 | (0.07) | (0.36) | (0.46) | (0.36) |
| Balance sheet | |||||||
| Total assets | - | 11.78 | 10.83 | 3.49 | 3.72 | 3.22 | 2.25 |
| Net worth | - | 11.78 | 10.84 | 3.49 | 3.72 | 3.22 | 2.25 |
| Total debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank | - | (0.02) | 8.43 | 0.02 | 0.01 | 0.02 | 0.01 |
| Net working capital | - | (0.54) | 8.19 | 0.01 | 0.00 | 0.01 | 0.03 |
| Cash flow | |||||||
| Cash from operations | - | 0.30 | (1.34) | (0.37) | 0.61 | 1.28 | (0.56) |
| Cash from investing | - | (9.30) | 3.63 | 0.38 | (0.62) | (1.27) | 0.54 |
| Cash from financing | - | 0.55 | 6.13 | 0.00 | 0.00 | 0.00 | 0.00 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.05 | 0.02 | 0.00 | 0.02 | 0.03 | (0.20) | 0.00 | 0.02 |
| Total expenses | 0.05 | 0.02 | 0.06 | 0.01 | 0.04 | 0.04 | 0.01 | 0.01 |
| EBITDA | (0.05) | (0.02) | (0.06) | (0.01) | (0.04) | (0.04) | (0.01) | (0.01) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | (0.06) | 0.01 | (0.01) | (0.24) | (0.01) | 0.01 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) | 0.00 | 0.00 |
Financial Statements
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.49 | 1.83 | 0.96 | 1.92 | 2.39 | 1.02 | 2.52 | 1.60 |
| Revenue growth (YoY) | -79.5% | +79.4% | -61.9% | +20.0% | - | - | - | - |
| Other income | 0.06 | 0.15 | 0.08 | 0.04 | 0.03 | (0.18) | 0.15 | 0.04 |
| EBITDA | (0.53) | (0.88) | (0.44) | (0.22) | 0.08 | (1.08) | (0.31) | 0.03 |
| EBITDA margin | -108.2% | -48.1% | -45.8% | -11.5% | +3.3% | -105.9% | -12.3% | +1.9% |
| Depreciation | 0.11 | 0.12 | 0.12 | 0.12 | 0.12 | 0.15 | 0.14 | 0.13 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | (0.23) | 0.11 | 0.13 |
| Profit before tax | (0.58) | (0.85) | (0.48) | (0.30) | (0.02) | (1.18) | (0.41) | (0.19) |
| Tax | 0.00 | (0.55) | 0.00 | 0.00 | 0.00 | (0.10) | (0.02) | 0.06 |
| Net profit | (0.58) | (0.30) | (0.48) | (0.30) | (0.02) | (1.08) | (0.39) | (0.25) |
| EPS (₹) | (2.56) | (2.96) | (1.29) | (1.29) | 0.25 | (13.68) | (3.06) | 5.46 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Revenue | 7.10 | 7.05 |
| Revenue growth | +0.7% | - |
| Other income | 0.31 | 0.38 |
| Total expenses | 8.57 | 9.31 |
| Employee cost | 0.00 | 1.96 |
| EBITDA | (1.47) | (2.26) |
| EBITDA margin | -20.7% | -32.1% |
| Depreciation | 0.48 | 0.54 |
| Interest | 0.02 | 0.01 |
| Profit before tax | (1.66) | (2.43) |
| Tax | (0.55) | (0.05) |
| Net profit | (1.11) | (2.38) |
| Net profit margin | -15.6% | -33.8% |
| EPS (₹) | (6.70) | (12.37) |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Equity & liabilities | ||
| Share capital | - | 1.92 |
| Reserves & surplus | - | 7.07 |
| Shareholders' funds (net worth) | - | 8.99 |
| Minority interest | - | 1.55 |
| Secured loans | - | 0.19 |
| Unsecured loans | - | 7.01 |
| Total debt | - | 7.20 |
| Total liabilities | - | 17.74 |
| Assets | ||
| Gross block | - | 21.38 |
| Net block | - | 12.03 |
| Capital work in progress | - | 0.00 |
| Investments | - | 2.46 |
| Inventories | - | 1.59 |
| Sundry debtors | - | 0.42 |
| Cash & bank balances | - | (0.27) |
| Loans & advances | - | 0.17 |
| Total current assets | - | 1.91 |
| Total current liabilities | - | 2.36 |
| Net working capital | - | (0.45) |
| Total assets | - | 17.74 |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Opening cash | - | 9.16 |
| Net cash from operating activities | - | (1.04) |
| Net cash from investing activities | - | (9.63) |
| Net cash from financing activities | - | 1.24 |
| Net change in cash | - | (9.43) |
| Closing cash | - | (0.27) |
| Particulars | FY 2025-26 | FY 2024-25 |
|---|---|---|
| Growth | ||
| Sales growth | +0.7% | - |
| EBITDA growth | +35.0% | - |
| PBT growth | +31.7% | +9997.0% |
| Net income growth | +53.4% | - |
| Profitability & leverage | ||
| Net income margin | -15.6% | -33.8% |
| Return on capital employed | - | 0.0% |
| Return on net worth | - | 0.0% |
| Debt / equity | - | 0.80 |
| Long-term debt / equity | - | 0.78 |
| Interest cover | -1.03 | -0.36 |
| Efficiency & per share | ||
| Fixed asset turnover | - | 0.33 |
| Inventory turnover | - | 4.43 |
| Debtors turnover | - | 16.79 |
| EPS (₹) | (6.70) | (12.37) |
| Dividend per share (₹) | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 46.93 |
| Particulars | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.05 | 0.02 | 0.00 | 0.02 | 0.03 | (0.20) | 0.00 | 0.02 |
| Total expenses | 0.05 | 0.02 | 0.06 | 0.01 | 0.04 | 0.04 | 0.01 | 0.01 |
| EBITDA | (0.05) | (0.02) | (0.06) | (0.01) | (0.04) | (0.04) | (0.01) | (0.01) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | 0.00 | 0.00 | (0.06) | 0.01 | (0.01) | (0.24) | (0.01) | 0.01 |
| Tax | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.04) | 0.00 | 0.00 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other income | 0.07 | 0.18 | 2.00 | 0.05 | 0.02 | 0.02 | 0.07 |
| Total expenses | 0.13 | 0.10 | 0.12 | 0.06 | 0.05 | 0.07 | 0.10 |
| Employee cost | 0.00 | 0.01 | 0.01 | 0.01 | 0.01 | 0.02 | 0.01 |
| EBITDA | (0.13) | (0.10) | (0.12) | (0.06) | (0.05) | (0.07) | (0.10) |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | (0.06) | 0.08 | 1.88 | (0.01) | (0.03) | (0.05) | (0.03) |
| Tax | 0.00 | 0.02 | 0.34 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net profit | (0.06) | (0.05) | 0.01 | (0.03) | (0.02) | (0.05) | (0.06) |
| EPS (₹) | (1.18) | 0.31 | 8.02 | (0.07) | (0.36) | (0.46) | (0.36) |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Equity & liabilities | |||||||
| Share capital | - | 1.92 | 1.92 | 1.04 | 1.04 | 1.04 | 1.04 |
| Reserves & surplus | - | 9.86 | 8.92 | 2.45 | 2.68 | 2.18 | 1.21 |
| Shareholders' funds (net worth) | - | 11.78 | 10.84 | 3.49 | 3.72 | 3.22 | 2.25 |
| Secured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Unsecured loans | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total debt | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total liabilities | - | 11.78 | 10.83 | 3.49 | 3.72 | 3.22 | 2.25 |
| Assets | |||||||
| Gross block | - | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 | 0.05 |
| Net block | - | 0.00 | 0.00 | 0.00 | 0.01 | 0.01 | 0.01 |
| Capital work in progress | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | - | 12.47 | 2.93 | 4.04 | 4.35 | 3.67 | 2.35 |
| Inventories | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sundry debtors | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash & bank balances | - | (0.02) | 8.43 | 0.02 | 0.01 | 0.02 | 0.01 |
| Loans & advances | - | 0.16 | 0.16 | 0.00 | 0.00 | 0.00 | 0.03 |
| Total current assets | - | 0.14 | 8.59 | 0.02 | 0.01 | 0.02 | 0.04 |
| Total current liabilities | - | 0.68 | 0.40 | 0.01 | 0.01 | 0.01 | 0.01 |
| Net working capital | - | (0.54) | 8.19 | 0.01 | 0.00 | 0.01 | 0.03 |
| Total assets | - | 11.78 | 10.83 | 3.49 | 3.72 | 3.22 | 2.25 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Opening cash | - | 8.43 | 0.02 | 0.01 | 0.02 | 0.01 | 0.03 |
| Net cash from operating activities | - | 0.30 | (1.34) | (0.37) | 0.61 | 1.28 | (0.56) |
| Net cash from investing activities | - | (9.30) | 3.63 | 0.38 | (0.62) | (1.27) | 0.54 |
| Net cash from financing activities | - | 0.55 | 6.13 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net change in cash | - | (8.45) | 8.42 | 0.01 | (0.01) | 0.01 | (0.01) |
| Closing cash | - | (0.02) | 8.43 | 0.02 | 0.01 | 0.02 | 0.01 |
| Particulars | FY 2025-26 | FY 2024-25 | FY 2023-24 | FY 2022-23 | FY 2021-22 | FY 2020-21 | FY 2019-20 |
|---|---|---|---|---|---|---|---|
| Growth | |||||||
| EBITDA growth | -30.0% | +16.7% | -100.0% | -20.0% | +28.6% | +30.0% | - |
| PBT growth | - | -95.7% | +9998.0% | +66.7% | +40.0% | -66.7% | -50.0% |
| Net income growth | -20.0% | -600.0% | +133.3% | -50.0% | +60.0% | +16.7% | - |
| EBITDA CAGR (3Y) | +29.4% | +26.0% | +19.7% | -15.7% | -5.9% | +5.3% | -20.6% |
| Profitability & leverage | |||||||
| Return on capital employed | - | -0.4% | +0.1% | -0.8% | -0.9% | -1.8% | -2.8% |
| Return on net worth | - | -0.4% | +0.1% | -0.8% | -0.9% | -1.8% | -2.8% |
| Debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Long-term debt / equity | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest cover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency & per share | |||||||
| Fixed asset turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debtors turnover | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS (₹) | (1.18) | 0.31 | 8.02 | (0.07) | (0.36) | (0.46) | (0.36) |
| Dividend per share (₹) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Book value per share (₹) | 0.00 | 61.51 | 56.56 | 33.55 | 35.76 | 30.92 | 21.63 |
To see the full year-wise statements and ratios of Skybiotech Healthcare Limited, buy the company report.
Board of directors of Skybiotech Healthcare Limited
Skybiotech Healthcare has 6 current directors and 12 former directors. Current directors are listed first, with their designation and appointment date.
| Name | Designation | Appointment Date | Tenure | Status |
|---|---|---|---|---|
| Poonam Prakash Rathi | Managing Director | 14 Feb 2005 | 21 Years 8 Months | Current |
| Rakesh Ramswaroop Somani | Director | 04 Sep 2017 | 9 Years 1 Months | Current |
| Yogesh Nandlal Chandak | Director | 14 Feb 2005 | 21 Years 8 Months | Current |
| Jagdish Manohar Mantri | Director | 07 Sep 2017 | 9 Years 1 Months | Current |
| Prakashchandra Rathi | Director | 28 Jun 2003 | 23 Years 3 Months | Current |
| Vijay Sitaram Chitlange | Director | 28 Aug 2025 | 1 Years 1 Months | Current |
Deals & funding
Skybiotech Healthcare Limited has 36 deals on record (36 market trades); the latest was in March 2025.
Deals on record (5 of 36)
| When | Deal | Amount | Parties |
|---|---|---|---|
| Mar 2025 | Market trade | ₹21.1 Lakh | Buyer: an individual Seller: Dear Shares Private Limited |
| Feb 2022 | Market trade | ₹20.1 Lakh | Buyer: an individual Seller: Subhmangal Merchandise Private Limited , 2 individuals |
| Jun 2021 | Market trade | ₹6.7 Lakh | Buyer: an individual Seller: Pantomath Finance Private Limited |
| May 2021 | Market trade | ₹4.6 Lakh | Buyer: Pantomath Finance Private Limited Seller: an individual |
| Mar 2021 | Market trade | ₹12 Lakh | Buyer: an individual Seller: Bangbhumi Distributors Private Limited , 2 individuals |
To see the full deal history of Skybiotech Healthcare Limited, buy the company report.
Deal records are compiled from filings and public sources; amounts are shown only where the source reported them.
Legal cases
No court or tribunal cases involving Skybiotech Healthcare Limited are on our record; a case search with case numbers, parties and status is in the company report Buy the company report.
MSME payment delays
No delayed payments to MSME suppliers are on our record for Skybiotech Healthcare Limited; the supplier-wise MSME Form 1 check is in the company report Buy the company report.
GST
Skybiotech Healthcare has 1 GST registration on record, and it has been cancelled or is inactive. Only active GST numbers are listed on this page.
To see the full GST registrations and return filing status of Skybiotech Healthcare Limited, buy the company report.
Recent activity
Skybiotech Healthcare Limited has 18 board changes on record since 2003: 8 appointments and 10 cessations. The latest: Vijay Sitaram Chitlange ceased to be Additional Director on 24 Sep 2025.
9 earlier events are in the company report.
Frequently asked questions
Skybiotech Healthcare is an active public limited company based in Mumbai, Maharashtra, India. The company works in business and IT consulting, within the business outsourcing industry. It was incorporated on 17 October 1983 (43+ years old) and is registered under CIN L21001MH1983PLC031114. Listed on BSE: 512036.
Skybiotech Healthcare reported revenue of ₹7.1 Cr for FY 2025-26 (up 0.7% YoY) based on consolidated financials.
Skybiotech Healthcare has 6 current directors:
- Poonam Prakash Rathi - Managing Director
- Rakesh Ramswaroop Somani - Director
- Yogesh Nandlal Chandak - Director
- Jagdish Manohar Mantri - Director
- Prakashchandra Rathi - Director
- Vijay Sitaram Chitlange - Director
The latest financial statements of Skybiotech Healthcare on record with the MCA are for the year ended 31 March 2026. Its last annual general meeting was held on 25 September 2025. Year-wise statements from 2015 are in the company report.
No. Skybiotech Healthcare has 1 GST registration on record and it is cancelled or inactive.
The CIN (Corporate Identification Number) of Skybiotech Healthcare is L21001MH1983PLC031114. It is issued by the Ministry of Corporate Affairs under the Companies Act, 2013, and uniquely identifies the company in India.
Yes. Skybiotech Healthcare is a listed company as per MCA records. Its shares are listed on BSE (code: 512036).
Skybiotech Healthcare was incorporated on 17 October 1983, making it 43+ years old. It is registered with the Registrar of Companies, Mumbai.
Skybiotech Healthcare has 36 deals on record (36 market trades); the latest was in March 2025.
Vijay Sitaram Chitlange ceased to be Additional Director on 24 Sep 2025. Vijay Sitaram Chitlange was appointed as Director on 28 Aug 2025. Nishi Jain was appointed as Company Secretary on 24 Jun 2025. Skybiotech Healthcare has 18 board changes on record in total.